We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
+2%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$339M
AUM Growth
+$36.2M
Cap. Flow
+$31.5M
Cap. Flow %
9.29%
Top 10 Hldgs %
40.44%
Holding
118
New
22
Increased
42
Reduced
29
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$9.37M
2
LH icon
Labcorp
LH
+$7.04M
3
JNJ icon
Johnson & Johnson
JNJ
+$6.49M
4
BDX icon
Becton Dickinson
BDX
+$5.83M
5
UHS icon
Universal Health Services
UHS
+$5.72M

Top Sells

Rank Stock Value
1
AMSG
Amsurg Corp
AMSG
+$5.97M
2
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
+$5.94M
3
HOLX
Hologic
HOLX
+$5.76M
4
CYH icon
Community Health Systems
CYH
+$4.33M
5
CAH icon
Cardinal Health
CAH
+$4.22M

Sector Composition

Rank Sector Weight
1 Healthcare 89.84%
2 Financials 0.85%
3 Technology 0.78%
4 Real Estate 0.25%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DHR icon
51
Danaher
DHR
$137B
$1.76M 0.52%
30,575
-30,501
-50% -$1.75M
TFX icon
52
Teleflex
TFX
$6.05B
$1.61M 0.48%
11,900
-32,600
-73% -$4.14M
EW icon
53
Edwards Lifesciences
EW
$49.6B
$1.58M 0.47%
+66,600
New +$1.5M
DVA icon
54
DaVita
DVA
$15.4B
$1.45M 0.43%
18,200
+15,553
+588% +$1.28M
AMGN icon
55
Amgen
AMGN
$208B
$1.41M 0.42%
9,200
+7,100
+338% +$1.14M
AMSG
56
DELISTED
Amsurg Corp
AMSG
$1.38M 0.41%
19,759
-89,341
-82% -$5.97M
ILMN icon
57
Illumina
ILMN
$31B
$1.36M 0.4%
6,419
-411
-6% -$80.3K
COR icon
58
Cencora
COR
$60.6B
$1.34M 0.4%
12,604
+2,504
+25% +$282K
NXTM
59
DELISTED
NxStage Medical Inc.
NXTM
$1.25M 0.37%
87,293
+20,200
+30% +$342K
CVS icon
60
CVS Health
CVS
$133B
$1.23M 0.36%
+11,700
New +$1.2M
PTCT icon
61
PTC Therapeutics
PTCT
$5.68B
$1.16M 0.34%
+24,100
New +$1.41M
ABT icon
62
Abbott
ABT
$183B
$1.1M 0.32%
22,350
+1,700
+8% +$81.6K
AFFX
63
DELISTED
Affymetrix Inc
AFFX
$1.06M 0.31%
+96,700
New +$1.17M
RAD
64
DELISTED
Rite Aid Corporation
RAD
$983K 0.29%
5,885
+600
+11% +$101K
LAB icon
65
Standard BioTools
LAB
$340M
$924K 0.27%
+38,200
New +$1.21M
MDVN
66
DELISTED
MEDIVATION, INC.
MDVN
$881K 0.26%
15,434
-25,866
-63% -$1.59M
OCRX
67
DELISTED
Ocera Therapeutics, Inc.
OCRX
$878K 0.26%
231,141
+71,939
+45% +$276K
VIRX
68
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$868K 0.26%
1,373
+706
+106% +$375K
UHT
69
Universal Health Realty Income Trust
UHT
$603M
$850K 0.25%
+18,300
New +$912K
NVRO
70
DELISTED
NEVRO CORP.
NVRO
$779K 0.23%
+14,500
New +$739K
SSRG
71
DELISTED
SYMMETRY SURGICAL INC COMMON STK
SSRG
$761K 0.22%
87,249
-48,803
-36% -$402K
GHDX
72
DELISTED
Genomic Health, Inc.
GHDX
$756K 0.22%
+27,200
New +$767K
MNK
73
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$743K 0.22%
6,309
-17,300
-73% -$2.13M
ANAC
74
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$720K 0.21%
9,300
-4,900
-35% -$321K
NBIX icon
75
Neurocrine Biosciences
NBIX
$16.8B
$712K 0.21%
+14,900
New +$632K
1 2
3
4 5

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q2 2015 Portfolio in Review

As of Q2 2015, Endurant Capital Management held 118 positions worth $339M, up 12% from $303M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Endurant Capital Management deployed $31.5M of net new capital in Q2 2015, opening 22 new positions and adding to 42 existing holdings. Its largest new stake was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 88% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amsurg Corp, an estimated $5.97M trimmed.

  • Endurant Capital Management's largest Q2 2015 buy was EndoChoice Holdings, Inc.: 328,501 shares worth $5.37M.
  • Endurant Capital Management added most to Merck in Q2 2015, an estimated $9.37M increase.
  • Endurant Capital Management's biggest Q2 2015 reduction was Amsurg Corp, cutting an estimated $5.97M.
  • Endurant Capital Management fully exited AUSPEX PHARMACEUTICALS INC COM STK (DE) in Q2 2015, selling an estimated $5.94M.
  • Endurant Capital Management's ten largest holdings make up 40% of its $339M portfolio in Q2 2015.
  • Endurant Capital Management opened 22 new positions and closed 25 in Q2 2015.
  • Endurant Capital Management's portfolio value rose 12% quarter-over-quarter to $339M.

Based on Endurant Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.